D935
Hypertension
Chong Kun Dang PharmaceuticalPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
34 Active assets in the Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VALSARTAN University of Alabama at Birmingham | Phase 4 | BBB |
Hydrochlorothiazide University of Kansas Medical Center | Phase 4 | BBB |
AMLODIPINE Jing Liu | Phase 4 | BBB |
Losartan Rong Zhang | Phase 4 | BBB |
OLMESARTAN MEDOXOMIL Virginia Polytechnic Institute and State University | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →